For three colorectal cancer patients and three pancreatic cancer patients, the vaccine appeared to remove all disease ...

Dr. Zev Wainberg of UCLA recently spoke with CURE about trial results concerning the cancer vaccine ELI-002 2P.

An 'off-the-shelf' vaccine may help prevent or delay cancer recurrence in people with hard-to-treat colorectal or pancreatic ...

New Phase I trial data finds that people who responded to ELI-002 survived longer and stayed cancer-free longer than usual.

The mKRAS-targeting cancer vaccine reduced the risk of death by 77% by activating the anti-tumour mechanisms of key immune ...

The vaccine would train the immune system to fight cancer-causing mutations, according to new research from UCLA Health.

A novel vaccine designed to target one of the most common cancer-driving mutations in patients with pancreatic and colorectal ...

An off-the-shelf cancer vaccine that targets KRAS mutations induced T-cell responses and was associated with impressive ...

A novel cancer vaccine that stimulates the immune system to target one of the most common cancer-driving mutations has shown ...

A new 'off-the-shelf' vaccine with the catchy name ELI-002 2P offers fresh hope for individuals affected by these deadly ...

Phase 1 trial of a pancreatic cancer vaccine targeting mutant KRAS shows strong immune responses, extended survival, and ...

A new vaccine aimed at a common cancer gene mutation could help stop aggressive pancreatic cancers from coming back, a small ...